Why Did Stan Druckenmiller Sell Broadcom Stock?
In Q3, legendary macro investor Stan Druckenmiller sold his entire…
Sell
5
VBIZF Quote, Financials, Valuation and Earnings
Last price:
$0.1900
Seasonality move
:
3194.18%
Day range:
$0.1939 - $0.1939
52-week range:
$0.0709 - $0.4294
Dividend yield:
0%
P/E ratio:
19.39x
P/S ratio:
1.78x
P/B ratio:
0.76x
Volume:
--
Avg. volume:
86
1-year change:
173.48%
Market cap:
$409.1M
Revenue:
$276M
EPS (TTM):
$0.01
Analysts' Opinion
-
Consensus RatingNo consensus rating exists at this time due to lack of analyst coverage.
-
Price Target DownsideNo price target exists because of limited analyst coverage.
-
Price Target UpsideSimilarly, at this time, analysts have not provided a price target so downside risk can't be assessed accurately at this time.
Fair Value
-
According to the consensus of 0 analysts, Viva Biotech Holdings has -- downside to fair value with a price target of -- per share.
VBIZF vs. S&P 500
-
Over the past 5 trading days, Viva Biotech Holdings has underperformed the S&P 500 by -20.56% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Viva Biotech Holdings does not have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Viva Biotech Holdings has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Viva Biotech Holdings reported revenues of --.
Earnings Growth
-
Viva Biotech Holdings has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Viva Biotech Holdings reported earnings per share of --.
Enterprise value:
438.6M
EV / Invested capital:
--
Price / LTM sales:
1.78x
EV / EBIT:
9.03x
EV / Revenue:
1.59x
PEG ratio (5yr expected):
-0.01x
EV / Free cash flow:
17.31x
Price / Operating cash flow:
17.28x
Enterprise value / EBITDA:
5.60x
Gross Profit (TTM):
$95.3M
Return On Assets:
-0.88%
Net Income Margin (TTM):
12.3%
Return On Equity:
-1.8%
Return On Invested Capital:
-1.17%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2024-01-01 | 2025-01-01 | 2025-01-01 | |||
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -- | -- | -- | -- | -- | |
| EBITDA | -- | -- | -- | -- | -- | |
| Diluted EPS | -- | -- | -- | -- | -- | |
| Period Ending | 2021-06-30 | 2022-06-30 | 2023-06-30 | 2024-06-30 | 2025-06-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $349.6M | $291.5M | $299.3M | $265.6M | -- | |
| Total Assets | $1.2B | $1.2B | $1.1B | $987.9M | -- | |
| Current Liabilities | $154.9M | $168.3M | $434.7M | $160.6M | -- | |
| Total Liabilities | $635.9M | $630M | $621.4M | $464.8M | -- | |
| Total Equity | $586.9M | $586.5M | $501.9M | $523.1M | -- | |
| Total Debt | $362.5M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2024-01-01 | 2025-01-01 | 2025-01-01 | |||
| Cash Flow Statement | ||||||
| Cash Flow Operations | -- | -- | -- | -- | -- | |
| Cash From Investing | -- | -- | -- | -- | -- | |
| Cash From Financing | -- | -- | -- | -- | -- | |
| Free Cash Flow | -- | -- | -- | -- | -- | |
VBIZF
Sector
Market Cap
$409.1M
$28.1M
Price % of 52-Week High
45.16%
50%
Dividend Yield
0%
0%
Shareholder Yield
0.75%
-1.54%
1-Year Price Total Return
173.48%
-17.67%
Beta (5-Year)
0.525
0.503
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.2272
200-day SMA
Sell
Level
$0.2578
Bollinger Bands (100)
Sell
Level
0.2404 - 0.3204
Chaikin Money Flow
Sell
Level
--
20-day SMA
Sell
Level
$0.2454
Relative Strength Index (RSI14)
Sell
Level
9.8791
ADX Line
Sell
Level
19.9344
Williams %R
Buy
Level
-100
50-day SMA
Sell
Level
$0.2649
MACD (12, 26)
Buy
Level
0.0581
25-day Aroon Oscillator
Sell
Level
-64
On Balance Volume
Sell
Level
-150
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (0.6685)
Buy
CA Score
(Annual)
Level (-0.1409)
Buy
Beneish M-Score
(Annual)
Level (-2.4749)
Buy
Momentum Score
Level (10)
Buy
Ohlson Score
Level (-0.8026)
Buy
Piotroski F Score
(Annual)
Level (8)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Viva Biotech Holdings engages in the discovery, development, and manufacturing of clinical drugs. It operates through Drug Discovery, and Contract Development Manufacture Organisation (“CDMO”) and Commercialization segments. The Drug Discovery segment involves in structure-based drug discovery services to biotechnology and pharmaceutical customers for their pre-clinical stage innovative drug development. The Contract Development Manufacture Organisation (“CDMO”) and Commercialization segment consists of contract development and manufacturing services for small molecule APIs and intermediates and trading of APIs, intermediates and formulations. The company was founded by Feng Mao Hua, Chen Cheney Mao and Ying Wu on August 27, 2008 and is headquartered in Shanghai, China.
Stock Forecast FAQ
In the current month, VBIZF has received 0 Buy ratings 0 Hold ratings, and 0 Sell ratings. The VBIZF average analyst price target in the past 3 months is --.
-
Where Will Viva Biotech Holdings Stock Be In 1 Year?
According to analysts, the consensus estimate is that Viva Biotech Holdings share price will drop to -- per share over the next 12 months.
-
What Do Analysts Say About Viva Biotech Holdings?
Analysts are divided on their view about Viva Biotech Holdings share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Viva Biotech Holdings is a Sell and believe this share price will rise from its current level to --.
-
What Is Viva Biotech Holdings's Price Target?
The price target for Viva Biotech Holdings over the next 1-year time period is forecast to be -- according to 0 Wall Street analysts, 0 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is VBIZF A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Viva Biotech Holdings is a --. 0 of 0 analysts rate the stock a -- at this time.
-
How Can I Buy Shares Of VBIZF?
You can purchase shares of Viva Biotech Holdings via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Viva Biotech Holdings shares.
-
What Is The Viva Biotech Holdings Share Price Today?
Viva Biotech Holdings was last trading at $0.1900 per share. This represents the most recent stock quote for Viva Biotech Holdings. Yesterday, Viva Biotech Holdings closed at $0.1939 per share.
-
How To Buy Viva Biotech Holdings Stock Online?
In order to purchase Viva Biotech Holdings stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get VBIZF Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
VBIZF
Sector
P/E ratio
19.39x
23.88x
PEG ratio
-0.01x
-0.01x
P/B ratio
0.76x
1.81x
Price / LTM sales
1.78x
1.59x
Growth Metrics
VBIZF
Sector
Revenue growth
--
4.73%
Earnings growth
--
11.11%
Revenue (5-year growth)
42.64%
6.46%
Earnings forecast
--
-$0.18
Profitability
VBIZF
Sector
Profitability FY 2024
$95.5M
$3.6M
Return on invested capital
-1.17%
-31.77%
Return on assets
-0.88%
-28.18%
Return on equity
-1.8%
-37.47%
Earnings Date
Last Earnings Date
Aug
28
Next Earnings Date
Mar
26
Estimated Next Earnings Date
Nov
27
Balance Sheet
VBIZF
Sector
Total cash
$129M
$26.3M
Short term investments
--
$26M
Total assets
$965.9M
$76.9M
Long term debt
--
$3.3M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Why Is CoreWeave Stock Down So Much?
AI cloud computing business CoreWeave (NASDAQ:CRWV) has been through a…
Why Did Stan Druckenmiller Buy MercadoLibre Stock?
In Q3, billionaire Stan Druckenmiller bought about 4,620 shares of…
Stock Ideas
Buy
55
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
53
Is AAPL Stock a Buy?
Market Cap: $4T
P/E Ratio: 36x
Buy
61
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 39x
Alerts
Sell
30
CORT alert for Jan 1
Corcept Therapeutics, Inc. [CORT] is down 50.44% over the past day.
Buy
75
AXSM alert for Jan 1
Axsome Therapeutics, Inc. [AXSM] is up 22.82% over the past day.
Sell
50
NUTX alert for Jan 1
Nutex Health, Inc. [NUTX] is down 9.81% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
